Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2221 |
| INN | Tabalumab |
| Status | Terminated |
| Drug code(s) | LY-2127399 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG4 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | Transgenic mouse |
| Target(s) | BAFF |
| Indications of clinical studies | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Myeloma, Multiple Sclerosis, Kidney Failure, Chronic |
| Primary therapeutic area | Immune-mediated / inflammatory disorders |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | January 01, 2004 |
| Start of Phase 2 | March 15, 2006 |
| Start of Phase 3 | December 15, 2010 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Eli Lilly and Company |
| Licensee/Partner | None |
| Comments about company or candidate | Studies in RA terminated in 2013; studies in lupus terminated in Oct 2014. Phase 1 study results published in Br J Clin Pharmacol. 2016 May; 81(5): 908–917. The initial phase 1 study of tabalumab included patients both with RA and SLE, as it was felt that tabalumab could be effective in both populations. Date of first phase 1 estimated. |
| Full address of company | Indianapolis, Indiana, United States North America United States of America https://www.lilly.com/contact-us |
B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B and B cell activating factor (aka BLyS)
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |